In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of ImmunityBio Inc (NASDAQ: IBRX) closed at $2.66 in the last session, up 2.31% from day before closing price of $2.60. In other words, the price has increased by $2.31 from its previous closing price. On the day, 9.44 million shares were traded.
Ratios:
We take a closer look at IBRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.05 and its Current Ratio is at 2.22.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 75.20.
Stock Price History:
Over the past 52 weeks, IBRX has reached a high of $7.63, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is 1.30%, while the 200-Day Moving Average is calculated to be -22.28%.
Shares Statistics:
A total of 853.39M shares are outstanding, with a floating share count of 91.82M. Insiders hold about 89.60% of the company’s shares, while institutions hold 9.09% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.44 and -$0.55 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.27, with 2.0 analysts recommending between -$0.26 and -$0.28.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $21.95M. It ranges from a high estimate of $24.5M to a low estimate of $20M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $1.05MFor the next quarter, 4 analysts are estimating revenue of $27.85M. There is a high estimate of $35.39M for the next quarter, whereas the lowest estimate is $22M.
A total of 4 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $124M, while the lowest revenue estimate was $83.52M, resulting in an average revenue estimate of $99.35M. In the same quarter a year ago, actual revenue was $14.74MBased on 4 analysts’ estimates, the company’s revenue will be $228.32M in the next fiscal year. The high estimate is $273.6M and the low estimate is $177.59M.
